Overview
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Status:
Recruiting
Recruiting
Trial end date:
2026-11-01
2026-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).Phase:
Phase 2/Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hospital Israelita Albert EinsteinTreatments:
Calcineurin InhibitorsCyclophosphamide
Thymoglobulin
Criteria
Inclusion Criteria:- Men and Women of Any Age
- Indication for an HSCT without matched sibling donor
- Have a matched unrelated donor (HLA 10 x 10 or 9 x 10)
- Hematological malignancy
Exclusion Criteria:
- Acute leukemias not in complete response (that is > 5% blast in the bone marrow)
- Chemorefractory lymphoproliferative disease
- Active uncontrolled infection
- HCT-CI > 3
- Severe organic disfunction (heart ejection fraction < 45%, glomerular filtration rate
< 50 mL.hour, pulmonary DLCO < 50%)
- Previous allogeneic bone marrow transplantation
- Contraindication to cyclophosphamide or ATG